According to a poster presentation given during the 2023 annual meeting of the American Academy of Ophthalmology, a travoprost implant was more effective for lowering IOP than topical PGA monotherapy.

Subjects who were taking prostaglandin analog (PGA) monotherapy were screened and then randomized to the slow-eluting travoprost (iDose TR; Glaukos) intraocular implant after a washout. Researchers compared the IOP of subjects at screening on PGA monotherapy to IOP of subjects in the slow-eluting implant group at month 3 (data from 2 phase 3 trials), coauthor Jason Bacharach, MD, reported.

The mean (SD) IOP was 5.8 (3.5) mmHg lower at screening compared to baseline, and 7.1 (4.3) mmHg lower at month 3 compared to baseline in these 125 subjects — a statistically significant 1.3 (4.0) mmHg greater IOP reduction while on the implant vs PGA monotherapy (t test, P<.0003).